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Abstract This predefined analysis of the European
Forsteo Observational Study (EFOS) aimed to describe
clinical fracture incidence, back pain, and health-related
quality of life (HRQoL) during 18 months of teriparatide
treatment and 18 months post-teriparatide in the subgroup
of 589 postmenopausal women with osteoporosis aged
C75 years. Data on clinical fractures, back pain (visual
analogue scale, VAS), and HRQoL (EQ-5D) were
collected over 36 months. Fracture data were summarized
in 6-month intervals and analyzed using logistic regression
with repeated measures. A repeated-measures model ana-
lyzed changes from baseline in back pain VAS and
EQ-VAS. During the 36-month observation period, 87
(14.8 %) women aged C75 years sustained a total of 111
new fractures: 37 (33.3 %) vertebral fractures and 74
(66.7 %) nonvertebral fractures. Adjusted odds of fracture
was decreased by 80 % in the 30 to \36–month interval
compared with the first 6-month interval (P \ 0.009).
Although the older subgroup had higher back pain scores
and poorer HRQoL at baseline than the younger subgroup,
both age groups showed significant reductions in back pain
and improvements in HRQoL postbaseline. In conclusion,
women aged C75 years with severe postmenopausal oste-
oporosis treated with teriparatide in normal clinical prac-
tice showed a reduced clinical fracture incidence by 30
months compared with baseline. An improvement in
HRQoL and, possibly, an early and significant reduction in
back pain were also observed, which lasted for at least 18
months after teriparatide discontinuation when patients
were taking other osteoporosis medication. The results
should be interpreted in the context of an uncontrolled
observational study.
JB Walsh has received honoraria for lectures from Servier, Eli Lilly
and Company, MSD and Amgen. WF Lems has received fees for
speaking/advisory boards from MSD, Warner Chilcott, Eli Lilly,
Amgen and Servier. BL Langdahl has participated on advisory boards
for Eli Lilly and Company, MSD, Amgen, Nycomed and Novartis,
has received research grants from Eli Lilly and Company, MSD,
Amgen and Novartis, and serves on Speaker’s Bureaus with Eli Lilly
and Company, MSD and Amgen. O Ljunggren has received lecture
fees from and participates as a clinical investigator and on advisory
boards for Eli Lilly, Amgen, Astra Zeneca and Nycomed.
A Fahrleitner-Pammer has received research grants from Amgen, Eli
Lilly and Company, Nycomed, Roche and Servier and has contributed
to Speaker’s Bureaus for Amgen, Daiichi Sankyo, Eli Lilly and
Company, Genzyme, GSK, MSD, Novartis, Nycomed, Roche, Sanofi-
Aventis and Servier. F Jakob has received honoraria for lectures and
advice from Eli Lilly, Amgen, Novartis, MSD, Nycomed, Servier and
Roche, has received unrestricted research grants from Novartis and is
involved in clinical studies related to osteoporosis drugs initiated by
Eli Lilly, Amgen, Servier and Novartis. F Marin is a full-time
employee and stock holder of Eli Lilly and Company. A Barrett is an
employee of Eli Lilly and Company. G Rajzbaum has consultant/
advisory role to Eli Lilly and Amgen. D Karras has nothing to
disclose.
J. B. Walsh
St. James’s Hospital and Trinity College, Dublin, Ireland
W. F. Lems
VU University Hospital, Amsterdam, The Netherlands
D. Karras
Veterans Administration Hospital, Athens, Greece
B. L. Langdahl
University Hospital, Aarhus, Demark
O. Ljunggren
Department of Medical Sciences, Uppsala University, Uppsala,
Sweden
A. Fahrleitner-Pammer
Medical University, Graz, Austria
123
Calcif Tissue Int (2012) 90:373–383
DOI 10.1007/s00223-012-9590-9
Keywords Age  Back pain  Fracture  Health-related
quality of life  Osteoporosis  Teriparatide
Osteoporotic fractures are a significant cause of morbidity
and mortality [1–3]. Such fractures, especially vertebral
fractures, can cause back pain, can reduce mobility and
physical functioning, and may impair health-related quality
of life (HRQoL) [4–6]. Age is an independent predictor of
osteoporosis and of all types of fracture [7–9]. The risk of
fracture is higher in older postmenopausal women than in
younger ones, even at the same level of bone mineral
density (BMD) [10]. The population of women aged 80
years or over is steadily increasing [11], and it has been
estimated that they contribute about 30 % of all fragility
fractures and more than 60 % of all nonvertebral fractures
[12].
Osteoporosis treatment aims to reduce the risk of
fracture, but evidence on the efficacy and use of medi-
cations in those at greatest risk, including elderly frail
subjects, is limited. Subgroup analyses from pivotal ran-
domized controlled trials (RCTs) have indicated that
osteoporosis medications, such as calcium and vitamin D,
alendronate, risedronate, zoledronic acid, strontium rane-
late, and denosumab, are effective at reducing the fracture
risk in older postmenopausal women with osteoporosis
[13–20]. Teriparatide (rhPTH1–34) is a bone anabolic
agent used to treat postmenopausal women and men with
severe osteoporosis who are at high risk of fracture. In a
subgroup of elderly women aged C75 years, teriparatide
significantly reduced the absolute risk for new vertebral
fractures by 9.9 % compared with the calcium and vita-
min D–supplemented placebo group over a median
duration of treatment of 19 months (relative risk reduction
65 %), similar to that seen in postmenopausal women
younger than 75 years [21]. RCTs have strict inclusion
criteria, and their findings may not be wholly applicable
to the broader range of osteoporosis patients seen in
everyday clinical practice. Observational studies are
conducted in the naturalistic setting without randomiza-
tion to treatment or exclusion of patients of advanced age
and/or those with comorbidities and taking comedications;
thus, they may have wider applicability [22].
The European Forsteo Observational Study (EFOS) was
an observational study in postmenopausal women with
osteoporosis treated with teriparatide in normal clinical
practice [23]. The participating women were aged between
39 and 92 years and were treated with teriparatide (20 lg
once daily by subcutaneous injection) for up to 18 months
and followed by a post-teriparatide treatment period of a
further 18 months. The overall fracture outcomes and back
pain over the 36-month follow-up for the total study cohort
were reported recently [24].
The aim of the present predefined analysis was to
describe the fracture outcomes, back pain, and HRQoL of
the subgroup of older women aged C75 years and to
compare the findings with those of the younger participants
(\75 years) of EFOS.
Methods
Study Design and Patients
EFOS was a multicenter, prospective, observational study
conducted in eight European countries (Austria, Denmark,
France, Germany, Greece, Ireland, the Netherlands, and
Sweden). The study design and characteristics of the
patient population have been described in detail elsewhere
[23]. Briefly, 1,649 postmenopausal women with a diag-
nosis of osteoporosis who were about to initiate teriparatide
treatment were enrolled. Patients were followed for the
duration of their teriparatide treatment, which they could
discontinue at any time, and were asked to return for two
additional visits after they discontinued teriparatide.
Patients were excluded from the study if they were cur-
rently being treated with an investigational drug or proce-
dure or had any contraindications as described in the
teriparatide label [25]. The observational design meant
there were no further restrictions for the selection of
patients, and all patient care provided was according to the
clinical judgment and usual practice of the participating
physicians.
Women provided written informed consent prior to
enrollment and were able to withdraw without consequence
at any time. The study was approved by local ethics
committees or review boards, depending on local require-
ments, and was conducted in accordance with the ethical
standards of the Declaration of Helsinki. The study was
conducted from April 2004 (first patient enrolled) until
February 2009 (last patient completed).
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Data Collection and Outcomes
Data collected at the baseline visit included patient demo-
graphic characteristics, risk factors for osteoporosis and
falls, drugs related to the risk of osteoporosis, and disease
status [23]. The number and type of prior and current med-
ications for the treatment of osteoporosis were recorded.
Teriparatide (20 lg once daily by self-administered
subcutaneous injection) was initiated at the baseline visit,
and women attended follow-up visits at approximately 3, 6,
12, and 18 months after teriparatide initiation and at 6 and 18
months after discontinuing teriparatide treatment. All oste-
oporosis treatment was at the discretion of the physician.
Diagnosis of osteoporosis was based upon axial or
peripheral dual-energy X-ray absorptiometric (DXA)
measurements of BMD and confirmed following review of
medical reports. Incident clinical vertebral and nonverte-
bral fragility fractures during the observational period were
diagnosed and confirmed by review of the original X-rays
and/or the radiology or surgical reports at the study site. A
new or worsened clinical vertebral fracture was defined as
the presence of a confirmed radiographic vertebral fracture
associated with signs and/or symptoms suggestive of a new
vertebral fracture [26].
Back pain was self-assessed by patients at each study
visit using a 100-mm visual analogue scale (VAS), ranging
from 0 = no back pain to 100 = worst possible back pain.
Patients also completed a back pain questionnaire that
captured the frequency and severity of back pain, limita-
tions of activities, and days in bed due to back pain in the
previous month [24].
HRQoL was measured at each visit using the European
Quality of Life Questionnaire (EQ-5D) [27], where patients
assess their perceived overall health status on a visual
analogue scale (EQ-VAS) that ranges from 0 = worst
imaginable health state to 100 = best imaginable health
state and classify their own health status according to five
dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), each of which is
scored on a three-point scale (no problems, some problems,
or extreme problems). The UK scoring algorithm was used
to calculate a single summary index, the Health State Value
(HSV), from the five EQ-5D dimensions [28].
Statistical Analysis
For data analyses, the total study cohort included all patients
with a baseline visit and at least one follow-up visit. Patients
were retrospectively categorized into one of two subgroups
according to their age at baseline: C75 or\75 years.
Descriptive statistics, such as frequencies, percentages,
means, standard deviations (SDs), and ranges, were used to
describe patients in the two subgroups. Between-group
comparisons were made using chi-squared or Fisher’s exact
tests (categorical variables) or the Kruskal-Wallis test
(continuous variables).
The number of fractures occurring in patients aged C75
or \75 years was summarized in 6-month intervals. For
each subgroup, a logistic regression with repeated mea-
sures was used to assess the change in number of patients
with one or more fractures over time [29, 30], giving an
analysis of the odds of one or more fractures, as described
for the total study cohort [24]. Patients were included in the
model at all observed intervals, irrespective of whether or
not they had fractured during a previous interval. The
repeated observations of each patient were assumed to be
related, but no further assumptions were made about the
relationship. Unadjusted and adjusted analyses (including
age, prior bisphosphonate use, and fracture in the last
12 months before starting teriparatide) were performed.
Contrasts were made between the odds of fracture in the
first 6 months of treatment (0 to \6 months) and each
subsequent 6-month interval.
Back pain and HRQoL were summarized over the teri-
paratide treatment period and after teriparatide discontinu-
ation for both age groups. Changes in back pain VAS from
baseline were analyzed using a mixed model of repeated
measures (MMRM), adjusting for back pain VAS at base-
line, number of previous fractures, age, diagnosis of rheu-
matoid arthritis, duration of prior bisphosphonate therapy,
and history of fracture in the 12 months before entering the
study. Changes from baseline in severity of back pain, fre-
quency of back pain, and limitation of activities due to back
pain at each follow-up visit were categorized as improve-
ment, no change, or worsening (defined by a change in the
categorical response for each question in the back pain
questionnaire); and the number/percent of patients improv-
ing/worsening was analyzed using the sign test.
A similar MMRM was used to assess the change from
baseline in EQ-VAS, including its baseline value. The sign
test analyzed the number/percent of patients reporting an
improvement or worsening from baseline in each of the
five EQ-5D domains, which was determined by assigning a
number to each of the three possible responses for each
domain and then determining whether the numerical dif-
ference between baseline and each time point was an
increase (improvement), no change, or a decrease (wors-
ening). Changes from baseline in EQ-5D HSV were
assessed using the Wilcoxon sign-rank test because this
parameter has a nonparametric distribution.
Results
Of the 1,581 patients in the total study cohort, 589 (37 %)
were aged C75 years and 992 (63 %) were\75 years. The
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disposition of patients during the study by age subgroup
(Fig. 1) shows that 76.7 and 56.0 % of patients aged
C75 years completed the 18- and 36-month visits, respectively.
Table 1 summarizes the demographic and baseline
characteristics of the patients in the two age groups (C75,
\75 years). At baseline, the older and younger subgroups
had similar lumbar spine BMD, prior bisphosphonate use,
and time since most recent fracture. However, the older
subgroup reported a higher frequency of risk factors asso-
ciated with falls and fractures (such as sight problems), a
higher number of prevalent fractures, and a history of falls.
Significantly more patients in the elderly subgroup had
diabetes mellitus or dementia and were taking concomitant
medications including antihypertensives, benzodiazepines,
antiarrhythmics, and anticoagulants/heparin. Furthermore,
the older subgroup had a higher mean back pain VAS and
poorer HRQoL as measured by the EQ-5D at baseline
compared with patients aged\75 years (Table 1).
Treatment
Median duration of teriparatide treatment was similar in
the two age groups: 543 days (Q1, Q3: 478, 553) for
patients C75 years and 543 days (Q1, Q3: 525, 555) for
patients \75 years. The reasons for discontinuation of
teriparatide in the subgroups aged C75 and \75 years,
respectively, were treatment completed (70.4 and 81.9 %),
patient decision (13.9 and 9.0 %), adverse event (9.0 and
6.8 %), physician decision (4.4 and 1.8 %), death (1.5 and
0.8 %), and noncompliance (0.8 and 0.3 %).
Of the 298 patients aged C75 years with data available
on osteoporosis medication taken after teriparatide was
discontinued, 95.6 % took some type of osteoporosis
medication. Most women took calcium (83.6 %) and vita-
min D (85.6 %), and 63.4 % were prescribed a bisphosph-
onate. Likewise, of the 611 patients aged \75 years with
data on osteoporosis medication taken after teriparatide was
discontinued, 93.6 % took an osteoporosis medication,
mainly a bisphosphonate (63.2 %), with most women also
taking calcium (84.9 %) and vitamin D supplementation
(86.5 %).
Fracture Outcomes
Table 2 summarizes the fracture incidence during teriparatide
treatment (0 to \18 months) and after teriparatide dis-
continuation (18 to\36 months) in the older (C75 years) and
younger (\75 years) subgroups. In the older subgroup, 87
Fig. 1 Patient disposition stratified by age \75 and C75 years
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(14.8 %) women sustained one or more fractures during the
36-month follow-up: 68 women sustained a single fracture
and 19 sustained two or more fractures. Of the 111 fractures,
37 (33.3 %) were clinical vertebral fractures and 74 (66.7 %)
were nonvertebral fractures; of all fractures, 54 (48.6 %) were
main-site nonvertebral fractures: forearm/wrist (n = 16), leg
(n = 13), hip (n = 11), sternum/ribs (n = 8), and humerus
(n = 6). The adjusted odds of fractures was not reduced
during the teriparatide treatment phase in the older subgroup
but was significantly lower in the last two time intervals (24 to
\30 months and 30 to\36 months) compared with the first
6-month interval (0 to \6 months); there was an 80 %
decrease in the odds of fracture in the 30 to\36–month period
compared to the first 6-month period (P \ 0.009) (Table 2).
In the subgroup of women aged\75 years, 121 (12.2 %)
sustained a total of 147 clinical fractures during the
Table 1 Baseline characteristics of the total study cohort (n = 1,581) stratified by age
Characteristic Age \75 years Age C75 years P
Patients, n (%) 992 (62.7) 589 (37.2)
Mean age, years (SD; range) 66.1 (6.4; 39–74) 79.2 (3.6; 75–92) NA
Caucasian (%) 99.1 99.4 0.550
Mean body mass index (SD) 25.3 (4.3) 24.9 (4.3) 0.173
Early menopause (\40 years) (%) 11.0 5.3 <0.001
Surgical menopause (%) 20.6 15.5 0.013
Nulliparous (%) 13.4 12.3 0.540
Sight problems (%) 37.5 57.7 <0.001
Osteoporotic hip fracture in biological mother (%) 22.6 17.7 0.036
Current smoker (%) 17.5 5.5 <0.001
Mean lumbar spine BMD T score (SD) -3.3 (1.1) -3.2 (1.3) 0.442
Bisphosphonate prior use (%) 72.2 75.6 0.142
Previous fracture (%) 85.8 92.0 <0.001
Previous fractures after 40 years of age, mean (SD) 2.7 (1.9) 3.3 (2.0) <0.001
C4 fractures after 40 years of age (%) 31.6 42.9 <0.001
Median time since most recent fracture, years (IQR) 0.7 (0.2–2.4) 0.7 (0.0–2.4) 0.888
At least one fracture in 12 months prior to study (%) 47.1 50.6 0.176
Assist with arms when standing up from chair (%) 59.9 69.1 <0.001
[1 fall in the last year (%) 21.0 26.5 0.009
Back pain and HRQoL
Mean back pain VAS, mm (SD) 56.5 (26.8) 59.8 (26.1) 0.019
Mean EQ-VAS (SD) 53.6 (21.8) 49.3 (22.0) <0.001
Median EQ-HSV (IQR) 0.62 (0.09–0.73) 0.52 (0.00–0.69) <0.001
Comorbidities (%)a
Rheumatoid arthritis 12.6 10.7 0.258
Chronic obstructive pulmonary disease 9.4 7.6 0.237
Diabetes mellitus 4.4 7.3 0.016
Dementia 0.1 1.0 0.008
Concomitant medication (taken at study entry) (%)a 61.3 68.0 0.008
Antihypertensives 34.4 42.0 0.003
Glucocorticoids 15.1 14.4 0.717
Benzodiazepines 10.6 14.4 0.025
Thyroid hormones 14.0 12.2 0.290
Antiarrhythmics 5.5 11.6 <0.001
Anticoagulants/heparin 4.8 10.3 <0.001
P values for group differences were calculated using t tests, Kruskal-Wallis tests, chi-squared tests, or Fisher’s exact test
a The three most frequent are listed plus any others that were significantly different between groups
SD standard deviation, BMD bone mineral density, IQR interquartile range, HRQoL health-related quality of life, EQ-VAS European Quality of
Life Questionnaire (EQ-5D) Visual Analogue Scale, EQ-HSV European Quality of Life Questionnaire (EQ-5D) Health State Value
The statistically significant P values in bold
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36-month follow-up (Table 2): 102 women (84.3 %) had a
single fracture and 19 (15.7 %) had two or more fractures.
Of the 147 fractures, 50 (34.0 %) were clinical vertebral
fractures and 97 (66.0 %) were nonvertebral fractures,
including 25, 16, 15, 11 and 8 fractures at the forearm/
wrist, hip, humerus, sternum/ribs, and leg, respectively.
There was a 71 % decrease in the odds of fracture in the
30 to \36–month period compared with the first 6-month
period (P \ 0.001) (Table 2).
Comparisons between the two age groups at each time
period showed that patients aged C75 years had a signifi-
cantly higher adjusted odds of fracture at 6 to\12 months
(OR = 2.11, 95 % CI 1.20–3.70; P = 0.010) and at 12
to \18 months (OR = 2.33, 95 % CI 1.24–4.35;
P = 0.008). There was no difference in the odds of fracture
between the older and younger groups at the other time
intervals.
Back Pain
The older subgroup of patients (C75 years) had signifi-
cantly higher mean back pain VAS scores (unadjusted) at
baseline and at 12, 18, and 24 months compared with the
younger subgroup (\75 years). There were statistically
significant reductions in adjusted back pain VAS scores
from baseline in both subgroups at each postbaseline visit
(Fig. 2). The decrease in back pain seen during teriparatide
treatment was maintained during the 18 months after teri-
paratide discontinuation. The reduction in back pain was
slightly greater in the younger group of patients; in the
adjusted model, the difference between age groups was
significant at 18, 24, and 36 months (P \ 0.05) but was less
than 5 mm at each visit (i.e., of little clinical significance).
Of the variables included in the MMRM, three were sig-
nificantly associated with the change in back pain VAS:
each additional 5 mm in baseline back pain VAS was
associated with a greater reduction in back pain of
-2.89 mm (95 % CI -2.71 to -3.07; P \ 0.001), a frac-
ture in the 12 months before study entry was associated
with a greater reduction in back pain VAS of -2.48 mm
(95 % CI -0.55 to -4.42; P = 0.0118) vs. no fracture, and
each additional previous fracture was associated with an
increase in back pain VAS of 1.09 mm (95 % CI 0.61–1.58;
P \ 0.001).
Table 3 summarizes the results from the back pain
questionnaire on back pain frequency, severity, and limi-
tations of activities due to back pain both during and after
teriparatide treatment for patients C75 and \75 years.
Table 2 Fracture incidence during teriparatide treatment (0 to \18 months) and after teriparatide was discontinued (18 to \36 months) in
patients aged C75 and \75 years
Time interval
(months)
n (missing/
unknown)
Fractures/ 10,000
patient years
Total
fractures
Patients with C1
fracture, n (%)a
ORb,c
(95 % CI)
P
Age C75 years
0 to \6 586 (3) 1,022 29 26 (4.4) – –
6 to \12 537 (1) 1,292* 33 28 (5.2) 1.17 (0.68–2.03) 0.564
12 to \18 485 (0) 978** 23 23 (4.7) 1.07 (0.60–1.90) 0.824
18 to \24 443 (1) 636 13 13 (2.9) 0.65 (0.33–1.27) 0.203
24 to \30 369 (3) 474 8 7 (1.9) 0.42 (0.18–0.98) 0.044
30 to \36 324 (0) 333 5 3 (0.9) 0.20 (0.06–0.67) 0.009
Total 586 (3) 111 87 (14.8)
Age \75 years
0 to \6 990 (2) 1,176 57 50 (5.0) – –
6 to \12 936 (1) 548 25 23 (2.5) 0.47 (0.30–0.76) 0.002
12 to \18 885 (1) 464 20 18 (2.0) 0.39 (0.22–0.67) 0.001
18 to \24 826 (1) 590 23 21 (2.5) 0.49 (0.29–0.84) 0.009
24 to \30 736 (1) 345 12 11 (1.5) 0.29 (0.15–0.56) <0.001
30 to \36 667 (0) 324 10 10 (1.5) 0.29 (0.15–0.57) <0.001
Total 990 (2) 147 121 (12.2)
n is the number of patients who attended the observation (number of patients with fracture data missing or unknown at this observation)
a As some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval
b Adjusted model by age, prior bisphosphonate use, and fracture in past 12 months before starting teriparatide
c Compared with 0 to \6 month interval
* P = 0.010 compared with the younger group, ** P = 0.008 compared with the younger group
The statistically significant P values in bold
378 J. B.Walsh et al.: Teriparatide in Elderly Women with Osteoporosis
123
Compared with the younger group, the older patients had a
higher frequency of back pain at baseline and at 3 and 6
months and a higher severity of back pain at baseline and 3
months. The older subgroup also had more severe limita-
tions of activities at every time point.
At every postbaseline visit, more patients in both sub-
groups reported an improvement than a worsening in back
pain frequency relative to baseline (sign test, P \ 0.001).
The same was true for severity of back pain and limitation
in activities due to back pain.
Health-Related Quality of Life
There were significant improvements from baseline in
adjusted mean EQ-VAS at all postbaseline visits in both
age groups of patients (Fig. 3). The increase in adjusted
EQ-VAS score was significantly higher in the younger age
group compared with the older age group at the 24-month
visit only. The unadjusted mean EQ-VAS scores show that
the older patients (C75 years) had a significantly poorer
HRQoL at baseline and at all follow-up visits (all
P \ 0.05) compared with the younger patients (\75 years).
A significantly higher percentage of patients in the older
subgroup reported some/extreme problems for each of the
EQ-5D domains compared with the younger age group
(Table 4). For all five domains at all postbaseline visits, a
greater percentage of patients in both age groups reported
an improvement than a worsening relative to baseline (sign
test, P \ 0.001).
In the older subgroup of women, median (Q1, Q3) HSVs
were increased significantly (Wilcoxon signed-rank test,
P \ 0.001) from baseline at all postbaseline visits and were
0.69 (0.52, 0.80) at both 18 and 36 months. The same was
observed in the younger age group, where the median
(Q1, Q3) HSVs were 0.73 (0.62, 1.00) and 0.76 (0.62, 1.00)
at 18 and 36 months, respectively.
Discussion
The results of this observational study show that elderly
women aged 75 years or above with severe postmenopausal
osteoporosis treated with teriparatide for up to 18 months
had a reduced clinical fracture incidence by 30 and 36
months compared with the first 6 months of treatment. In
addition, these older patients reported an early and signifi-
cant reduction in back pain and improvement in HRQoL
during teriparatide treatment, which was sustained after
teriparatide was discontinued, during which time most
patients were receiving some osteoporosis medication,
mainly calcium, vitamin D, and a bisphosphonate. Of note,
the majority of the elderly patients who received teriparatide
had previously been treated with a potent antiresorptive for
their severe bone disease and were also receiving calcium
and vitamin D supplements during the course of teriparatide
treatment. These findings suggest that teriparatide is an
effective treatment in elderly postmenopausal women aged
75 years and above at very high risk of fracture when used as
part of a sequential treatment regimen.
Age is a major determinant of bone strength and fracture
risk in postmenopausal women. Bone loss (both trabecular
and cortical) occurs with advancing age, with decreases in
both bone mass and bone quality [31]. Bone fragility
increases with age because of changes in microarchitecture
and an accumulation of microdamage and hypomineral-
ization [12]. In elderly women with postmenopausal oste-
oporosis, age-related bone loss is superimposed on loss of
bone caused by estrogen deficiency [31, 32]. Moreover,
vitamin D deficiency is common in elderly people and can
lead to secondary hyperparathyroidism and PTH-induced
bone loss [31].
Our findings in patients treated in normal life conditions
are consistent with and complement those of the random-
ized, placebo-controlled Fracture Prevention Trial, where
the incidence of new vertebral fractures during approxi-
mately 18 months of teriparatide treatment (relative to
placebo) was comparable in younger (\75 years) and older
Fig. 2 Back pain VAS: least squares (LS) mean change from
baseline during and after teriparatide treatment in subgroups of
patients aged \75 and C75 years. Back pain VAS range 0–100 mm.
All values in both groups P \ 0.001 versus baseline. *P \ 0.05
versus elderly subgroup (age C75 years). Data are from MMRM
analysis. Model included baseline back pain VAS, number of
previous fractures, fracture in 12 months before study entry, age,
prior bisphosphonate duration, diagnosis of rheumatoid arthritis, and
visit, where repeated measures were modeled with an unstructured
correlation matrix. In the elderly subgroup (C75 years), the
unadjusted mean (SD) back pain VAS scores at baseline, 3, 6, 12,
18, 24, and 36 months and end of study (LOCF) were 59.8 (26.1),
44.0 (24.1), 39.5 (23.9), 36.8 (24.3), 34.7 (24.3), 34.9 (26.2), 31.4
(26.1) and 37.3 (27.1) mm, respectively. The corresponding values for
the younger subgroup (\75 years) were 56.5 (26.8), 42.3 (25.5), 37.7
(26.2), 33.4 (26.3), 30.4 (26.0), 30.7 (26.9), 28.3 (26.4), and 31.3
(27.2) mm
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(C75 years) patients [21]. Thus, in women aged 75 and
above, 5.2 % in the teriparatide group and 15.1 % in the
placebo group had new vertebral fractures (relative risk
reduction 65 %).
Because this is an observational, nonrandomized study,
it is difficult to compare the incidence of fractures between
the two age groups. Nevertheless, the adjusted odds of
fracture were higher in the elderly group during the 6–18
months of teriparatide treatment compared with the
younger group but were similar between age groups during
the 18-month post-teriparatide treatment period. The higher
fracture risk during the 6–18 months of teriparatide treat-
ment in patients aged C75 years may be a consequence of
the additional age-related risk factors in these older women
and their higher risk of fracture at baseline, as reflected in
the greater frequency of prevalent fractures, falls, and
dementia as well as use of concomitant medications.
Evidence for the antifracture efficacy of other antioste-
oporosis drugs in postmenopausal women aged C75 years
with osteoporosis is also based on subgroup analyses of
data from randomized, placebo-controlled studies. These
studies have shown that treatment with alendronate,
risedronate, zoledronic acid, strontium ranelate, and
denosumab is associated with a reduction in the risk of new
clinical fractures after 3 years [14–18, 20, 33]. Data from
the Fracture Intervention Trial showed that alendronate
reduced the risk of new vertebral fractures by 38 % (rela-
tive to placebo) in the subgroup of women aged C75 years
during an average follow-up of 2.9 years [14] and that the
absolute risk reduction for combined clinical hip, spine,
Table 3 Back pain questionnaire results for subgroups of patients C75 and \75 years
During teriparatide treatment period After teriparatide discontinued
Baseline 3 months 6 months 12
months
18
months
24
months
36
months
End of study
(LOCF)f
Frequency of back paina
Age C75 years (n = 584) (n = 544) (n = 513) (n = 463) (n = 444) (n = 376) (n = 320) (n = 557)
Every day/almost every day (%) 68.8* 39.3* 34.3* 32.2 28.8 27.7 22.5 31.4
Age \75 years (n = 985) (n = 916) (n = 898) (n = 858) (n = 827) (n = 708) (n = 670) (n = 962)
Every day/almost every day (%) 59.8 33.2 31.3 27.0 23.9 23.0 20.3 24.2
Severity of back painb
Age C75 years (n = 551) (n = 503) (n = 465) (n = 417) (n = 388) (n = 315) (n = 262) (n = 475)
Severe (%) 51.0* 20.9* 14.8 14.4 11.6 13.0 11.5 16.0
Age \75 years (n = 930) (n = 817) (n = 775) (n = 675) (n = 640) (n = 532) (n = 486) (n = 730)
Severe (%) 41.9 17.0 14.6 13.2 11.4 13.0 12.6 15.3
Limitation of activities due to back painc
Age C75 years (n = 552) (n = 504) (n = 465) (n = 417) (n = 390) (n = 316) (n = 262) (n = 475)
Severe (%) 42.6* 18.5* 11.8* 14.6* 13.1* 15.2* 13.7* 17.1*
Age \75 years (n = 930) (n = 815) (n = 773) (n = 675) (n = 641) (n = 536) (n = 487) (n = 731)
Severe (%) 34.2 16.2 13.6 10.2 8.6 11.4 11.3 13.4
Days in bed due to back paind
Age C75 years (n = 549) (n = 502) (n = 467) (n = 415) (n = 388) (n = 314) (n = 261) (n = 473)
At least 1 (%) 23.5 9.8 9.4 8.4 8.0 10.5 8.8 10.6
Median (Q1, Q3)e 10 (3, 20) 5 (3, 10) 3 (2, 8) 4 (2, 10) 7 (2, 11) 4 (2, 10) 3 (2, 6) 4 (2, 10)
Age \75 years (n = 930) (n = 816) (n = 773) (n = 675) (n = 640) (n = 536) (n = 486) (n = 732)
At least 1 (%) 19.8 7.4 5.0 4.4 3.9 6.0 4.3 6.4
Median (Q1, Q3)e 6 (3, 15) 3 (2, 7) 3 (1, 5) 3 (2, 5) 3 (2, 6) 3 (2, 7) 3 (2, 4) 3 (2, 6)
Total n varies for each variable due to missing data. The percentages given for each variable refer to the total n available for that variable
a Categories were no pain, once or twice, a few times, fairly often, every day or almost every day (during the past month)
b Categories were minor, moderate, severe (during the past month)
c Categories were no limitation, minor extent, moderate extent, severe extent (during the past month)
d In the past month
e For those patients with at least 1 day in bed due to back pain during the last month
f Missing data were handled using the last observation carried forward (LOCF) method
* P \ 0.05 for comparison with patients aged \75 years (Cochran-Mantel-Haenzsel test). A greater percentage of patients in both age groups
reported an improvement than a worsening relative to baseline at all postbaseline visits (sign test, P \ 0.001)
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and wrist fractures was greatest in the 75–85 year age
group [33]. For risedronate, there was a significant 44 %
reduction in the risk of vertebral fractures (relative to
placebo) in women aged 80 years or above but no signif-
icant difference in the incidence of nonvertebral fractures
[15]. A pooled analysis of RCTs in postmenopausal women
with osteoporosis found that, despite a 4 % increase in the
risk of fracture for every 1-year increase in age, there was a
46 % reduction in the risk of clinical fracture over 3 years
with risedronate treatment [17]. For zoledronic acid, post
hoc subgroup analysis of pooled data from the HORIZON
trials found significant reductions (vs. placebo) in the risk
of any clinical fracture (35 %), clinical vertebral fractures
(66 %), and nonvertebral fractures (27 %) in postmeno-
pausal women aged C75 years [16]. For strontium ranelate,
pooled data from the SOTI and TROPOS studies revealed
risk reductions of 32 %, 31 %, and 22 % for vertebral,
nonvertebral, and clinical fractures after 3 years in women
aged 80 years or above with osteoporosis [18]. In a post
hoc analysis of the 3-year randomized, double-blind, pla-
cebo-controlled FREEDOM study, denosumab treatment
significantly reduced the risk of hip fractures by 62 %
(relative to placebo) in the subgroup of postmenopausal
women aged 75 years or above [20]. Moreover, a recent
meta-analysis of the efficacy of antiresorptive therapy in
elderly women with osteoporosis found that vertebral
fracture risk reduction increased with age and duration of
treatment [34].
A main finding of the present study is that both age groups
experienced rapid and significant improvements in back pain
and HRQoL during teriparatide treatment. These benefits
were maintained after teriparatide was discontinued when
most patients were receiving other osteoporosis medication.
The higher back pain scores and poorer HRQoL in the older
subgroup (C75 years) throughout the study may reflect
greater severity of osteoporosis in this subgroup of patients.
There are several limitations of the EFOS study that
should be considered when interpreting the data from these
analyses. First, as this was an observational study, patients
were not randomized by age or to treatment, and there was no
comparator group to teriparatide. As a result, we cannot
attribute the observed changes to teriparatide treatment.
Moreover, as the majority ([93 %) of patients took an
osteoporosis medication during the 18-month post-
teriparatide treatment period, we cannot exclude the effects
of this sequential therapy on the observed responses. Second,
we may have underestimated the fracture incidence because
only symptomatic vertebral fractures were confirmed by
radiology. Third, data on analgesic use during the study were
not gathered; this may have affected the back pain results.
The strengths of this study include the large sample size,
with no age limit restrictions, and inclusion of a diverse range of
patients, many of whom had comorbidities and were taking
concomitant medications. Another advantage of the study is
that the participating postmenopausal women with severe
osteoporosis received teriparatide as part of different sequential
therapies, reflecting treatment as it occurs in the normal clinical
practice setting. Moreover, we examined fracture incidence,
back pain, and quality of life both during and after teriparatide
treatment and adjusted for factors that may influence the
changes, including previous bisphosphonate use and fracture in
the 12 months before starting teriparatide.
The need for osteoporosis medications that are safe and
well tolerated is especially important in elderly patients,
who are likely to have comorbidities and to be taking
concomitant medications. The safety of teriparatide has
already been established, and results from the placebo-
controlled Fracture Prevention Trial have shown that teri-
paratide was well tolerated in elderly patients, with no
significant differences in the safety profile between patients
C75 and\75 years [21]. Safety was not an objective of the
present observational study.
Conclusion
Patients with severe postmenopausal osteoporosis aged
75 years or above treated with teriparatide showed a reduced
Fig. 3 HRQoL: least squares (LS) mean change from baseline in
EQ-VAS in older (C75 years) and younger (\75 years) women both
during teriparatide treatment for 18 months and in the 18 months after
teriparatide was discontinued. EQ-VAS range 0–100. All values in
both groups P \ 0.001 versus baseline. *P \ 0.001 versus elderly
subgroup (age C75 years). Model includes baseline EQ-VAS score,
number of previous fractures, fracture in 12 months before study
entry, age, prior bisphosphonate use duration, and diagnosis of
rheumatoid arthritis. For women aged C75 years, unadjusted mean
(SD) EQ-VAS values at baseline, 3, 6, 12, 18, 24, and 36 months and
end of study (LOCF) were 49.3 (22.0), 55.7 (19.2), 58.6 (19.2), 60.5
(20.9), 63.8 (20.9), 63.2 (22.2), 65.4 (22.2), and 60.4 (22.7),
respectively. The corresponding values for the younger women were
53.6 (21.8), 60.9 (20.0), 63.8 (20.3), 66.7 (21.4), 69.4 (21.4), 69.6
(22.3), 70.3 (22.4), and 67.4 (23.2)
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incidence of clinical fractures by 30 months compared with
baseline, together with improvements in HRQoL and pos-
sibly an early and significant reduction in back pain. These
outcomes lasted for at least 18 months after teriparatide
discontinuation when patients were taking other osteoporo-
sis medication. These results should be interpreted in the
context of an uncontrolled observational study.
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